| Company/Division name | Novartis |
| Parent company | Novartis |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2026 |
| Year reshoring implemented or to be implemented: | 2029 |
| Domestically, the work will be done: | In-house |
| Country(ies) from which reshored: | Switzerland |
| City reshored to: | Winter Park |
| State(s) reshored to: | FL |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | radioligand therapy (RLT) manufacturing facility |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Skilled workforce availability/training |
